ClinicalTrials.gg
RecruitingNCT07724132AD-SMARTUpdated Jul 23, 2026

An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease

A Phase 3 interventional study of Placebo and Atomoxetine in Alzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease and Alzheimer Disease Dementia, sponsored by University College, London. Recruiting at 2 sites in United Kingdom. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by University College, London · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 261 studies in Alzheimer Disease with a site in United Kingdom — 43 open to participants now, 69 under way, 26 of them phase 3. Alzheimer Disease · United Kingdom.

Planned enrollment
26th of 226
1,200 · median 280
Started
2026
with 13 others
Phase 3
84 of 261
10 open now
Primary completion
2031-03
later than 61 of 68 live
Registered
245th of 261
by date
Lead sponsor
6 of 261
University College, London

Among the 261 studies in Alzheimer Disease with a site in United Kingdom, this one is the 26th largest by planned enrollment of the 226 interventional ones that give a count, is one of 14 that started in 2026, is one of 84 in phase 3, reaches primary completion later than 61 of the 68 other live ones, and was the 245th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

43 of the 261 studies in Alzheimer Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 261 studies in Alzheimer Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

A multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease in a population representative of people with Alzheimer's disease in the UK.

Read the detailed description

AD-SMART is a platform trial using a multi-arm multi-stage (MAMS) adaptive design.

Participants are randomised (1:1:1) to standard of care plus placebo, atomoxetine, or metformin. Interim analyses are conducted in stages (Stage 1, Stage 2, and Stage 3) to determine whether treatment arms should continue or stop early for lack of activity.

The primary objective is to assess therapeutic benefit by measuring change in cognitive function and activities of daily living over 18 months. Secondary outcomes include neuropsychiatric symptoms, quality of life, caregiver burden, safety, and health economic outcomes.

Exploratory analyses include blood biomarkers and MRI imaging to investigate disease progression and treatment response.

03

Conditions studied

  • Alzheimer's Disease (AD)
  • Mild Cognitive Impairment Due to Alzheimer's Disease
  • Alzheimer Disease Dementia
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient meets all inclusion criteria:

    1. Adults aged ≥55 years on the day of screening, no upper age limit 2. Either:

    1. Confirmed clinical diagnosis of Alzheimer's Disease (AD)
    2. Confirmed clinical diagnosis of Mixed Dementia consisting of Alzheimer's Disease and Vascular Dementia 3. score of ≥17 4. Confirmatory blood biomarker testing (pTau-217) (positive or intermediate via validated assays) ≤ 365 days prior to screening or between screening and randomisation or a positive amyloid PET scan (if available) or a positive amyloid CSF test (if available) 5. Randomisation should ideally take place within 4 weeks of the screening visit but no later than 8 weeks after the screening visit 6. Must be able and willing to comply with the treatment and assessment schedule and requirements including being able to start trial treatment ≤ 2 weeks after randomisation 7. Willing and able to have MRI scans in accordance with the assessment schedule unless participant is clinically due to:

    <!-- -->

    1. Pacemakers or defibrillators (unless MRI-conditional models)
    2. Aneurysm clips, stents or metal implants (unless MRI safe)
    3. Cochlear implants (unless MRI-conditional models)
    4. Metal fragments in the body
    5. Severe claustrophobia 8. Negative pregnancy test ≤4 weeks prior to randomisation for women of 9. Normal liver function at screening consisting of all the following:

    <!-- -->

    1. Total serum \<1.5 x (except for participants with Gilbert's disease, for whom the upper limit of total serum bilirubin is 51.3 μmol/l or 3mg/dl)
    2. (ALT) \<3 x ULN;
    3. Alkaline phosphatase \<3 x ULN 10. Documented participant and study partner 11. If a participant is being re-randomised into the trial, additional timing of entry requirements must also be met:

    <!-- -->

    1. For participants being re-randomised after completing 18 months' follow-up and the arm was not closed due to lack of activity, a 12-week from last dose of IMP must be completed before their screening visit. If the efficacy analysis indicates that the IMP was ineffective then this washout period can be reduced to 6 weeks.
    2. For participants being re-randomised following treatment arm termination due to lack of activity, a 6-week washout period from their last dose of IMP must be completed prior to screening assessment

      Study Partner inclusion criteria:

      1. Participant that meets the AD-SMART eligibility criteria has consented to participation in the trial
      2. Has at least twice-weekly contact with participant
      3. Be 18 years or older at the time of providing consent
      4. Willing to complete study partner questionnaires as outlined in visit schedule
      5. Willing to attend remote and in-person study visits with participant
      6. Documented informed consent

Exclusion criteria

Exclusion Criteria:

  • Patient meets none of the exclusion criteria:

    1. Fazekas Score =3 reported from an MRI taken at any time prior to randomisation, if an MRI is not clinically (reasons specified in Inclusion Criteria 7) A. MRI does not need to be repeated if Fazekas score = 0, 1 or 2 reported from an MRI performed ≤365 days to screening visit (if Fazekas score has not been reported, refer to Section 7.4) b. MRI should be conducted if participant is not clinically contraindicated to MRIs and previous MRI where Fazekas score = 0, 1 or 2 was >365 days or previous MRI scan is not available for Fazekas score reporting or participant has never had an MRI
    2. Clinical diagnosis of Dementia with Lewy bodies
    3. Clinical diagnosis of Parkinson's disease
    4. Clinical diagnosis of Frontotemporal Dementia
    5. Cardiac failure (American Heart Association Stage C or D)
    6. Significant respiratory comorbidity (hospitalisation within the previous ≤6 months due to respiratory comorbidity)
    7. Renal failure (CKD IV or ≤45 mL/min/1.73m²) at any time point prior to randomisation
    8. (except if in complete remission) e.g. solid organ or haematological or melanoma
    9. Score of ≥1 on C-SSRS at screening visit
    10. Individuals without an identified study partner (refer to Section 4 for further details on study partners)
    11. Individuals who have an Alzheimer's Disease or Central Nervous System medication (e.g. antidepressant) change or dose change ≤28 days prior to screening
    12. Use of an Medicinal Product (IMP) or Investigational Medical Device (IMD) ≤26 weeks prior to randomisation (except for AD-SMART participants that are being re-randomised. See Section 5.4 for further information).
    13. Receiving antibody-based amyloid clearing treatment for Alzheimer's Disease within 26 weeks prior to randomisation
    14. Unable or unwilling to comply with study procedures
    15. Unable to swallow whole capsules
    16. Individuals who are living in the same household as an AD-SMART participant who is actively taking trial medication
    17. Female participants that are pregnant or breastfeeding
    18. Women of (WOCBP) who are unwilling or unable to use an acceptable method of (see acceptable methods of contraception) whilst on trial treatment and up to 12 weeks after the last dose of study drug
    19. Male participants with a partner of child-bearing potential unwilling or unable to use an acceptable method of contraception whilst on trial treatment and up to 12 weeks after the last dose of the study drug.
    20. Male participants unwilling to desist from sperm donation during the trial and for 12 weeks after the last dose of trial treatment
    21. Current or previous exposure to any of the currently recruiting AD-SMART IMPs ≤26 weeks before randomisation.
    22. History of alcohol and/or drug abuse and/or dependence within the 5 years prior to screening visit.
    23. Any concurrent medical condition, abnormal laboratory tests or uncontrolled, systemic disease that, in the opinion of the Investigator, could cause study participation to be detrimental to the participant.
    24. Participants who are not eligible for any of the trial IMPs, according to the eligibility criteria listed in the individual drug appendices. Please note that participants can enter the trial if they are eligible for at least one of the trial treatment arms, but do not need to be eligible for all.

Arm-specific eligibility criteria:

Atomoxetine-specific exclusion eligibility criteria:

In addition to the core inclusion and exclusion criteria, refer to section 2.2 of AD-SMART Appendix 1 Atomoxetine' for the arm-specific exclusion eligibility criteria for the Atomoxetine arm which must also be met.

Metformin-specific exclusion eligibility criteria:

In addition to the core inclusion and exclusion criteria, refer to section 2.2 of AD-SMART Appendix 2 Metformin' for the arm-specific exclusion eligibility criteria for the metformin arm which must also be met.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,200 participants (estimated)

Study arms

  • Placebo comparator
    Standard of Care + Placebo

    Placebo arm (Oral capsule matching active treatments)

    Drug: Placebo

  • Active comparator
    Standard of Care + Atomoxetine

    Atomoxetine (Oral, up to 100 mg/day)

    Drug: Atomoxetine

  • Active comparator
    Standard of Care + Metformin

    Metformin (immediate release) Oral, up to 2000 mg/day

    Drug: Metformin 1000 mg Oral Tablet

Interventions

  • DrugPlacebo

    Oral capsule matching active treatments

  • Atomoxetine (Oral, up to 100 mg/day)

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metformin IR Oral, up to 2000 mg/day

06

What researchers measure

Primary outcomes

  1. Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score

    The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) measures the severity of cognitive impairment in dementia. Scores range from 0 to 70, with higher scores indicating worse cognitive performance (Unit of Measure: ADAS-Cog score (0-70). ADAS-Cog will be administered at baseline, month 6, month 12, and month 18 (end of study), and change over time will be assessed.

    Time frame: Baseline to 18 months

  2. Change in Amsterdam Instrumental Activities of Daily Living Questionnaire - Short Version (A-IADL-Q-SV) score

    The Amsterdam Instrumental Activities of Daily Living Questionnaire - Short Version (A-IADL-Q-SV) assesses functional impairment in instrumental activities of daily living. Scores range from 0 to 100, with higher scores indicating better functional performance (Unit of Measure: A-IADL-Q-SV score (0-100). The A-IADL-Q-SV will be administered at baseline, month 6, month 12, and month 18 (end of study), and change over time will be evaluated.

    Time frame: Baseline to 18 months

Secondary outcomes

  1. Change in Neuropsychiatric Inventory (NPI) total score

    The Neuropsychiatric Inventory (NPI) is a structured, informant-based interview assessing neuropsychiatric and behavioural symptoms across 12 domains. Total scores range from 0 to 144 (Unit of Measure: NPI total score (0-144)), with higher scores indicating more severe neuropsychiatric symptoms. The NPI will be administered at baseline, month 6, month 12, and month 18 (end of study), and change over time will be evaluated.

    Time frame: Baseline to 18 months

  2. Change in EQ-5D-5L health-related quality-of-life score (participant-reported)

    The EQ-5D-5L (EuroQol 5-Dimension 5-Level) questionnaire measures participant-reported health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index score ranging from less than 0 (health states worse than death) to 1 (full health), with higher scores indicating better health-related quality of life (Unit of Measure: EQ-5D-5L utility score (\<0 to 1)). The EQ-5D-5L will be administered at baseline, month 3, month 6, month 12, month 15, and month 18 (end of study), and change over time will be assessed.

    Time frame: Baseline to 18 months

  3. Change in EQ-5D-5L health-related quality-of-life score (study partner-reported)

    The EQ-5D-5L (EuroQol 5-Dimension 5-Level) questionnaire measures study partner-reported health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index score ranging from less than 0 (health states worse than death) to 1 (full health), with higher scores indicating better health-related quality of life (Unit of Measure: EQ-5D-5L utility score (\<0 to 1)). The EQ-5D-5L will be administered at baseline, month 6, month 12, and month 18 (end of study), and change over time will be assessed.

    Time frame: Baseline to 18 months

  4. Change in Zarit Burden Interview (ZBI) total score

    The Zarit Burden Interview (ZBI) assesses subjective caregiver burden, including emotional, social, and physical strain associated with providing care. Total scores range from 0 to 88, with higher scores indicating greater caregiver burden (Unit of Measure: ZBI total score (0-88)). The ZBI will be administered at baseline, month 6, month 12, and month 18 (end of study), and change over time will be evaluated.

    Time frame: Baseline to 18 months

  5. Incidence of treatment-emergent adverse events and serious adverse events

    Safety profile of investigational medicinal products (IMPs), including all adverse events (AEs), serious adverse events (SAEs), adverse reactions (ARs), and suspected unexpected serious adverse reactions (SUSARs). Events will be systematically collected, assessed, and analysed throughout the study from first dose until end of follow-up (Unit of Measure: Number of participants experiencing at least one AE or SAE)

    Time frame: Baseline to 18 months

  6. Change in health and social care resource use and associated costs

    Health and social care resource utilisation will be measured using a structured Resource Use Questionnaire (RUQ). The RUQ captures participant use of primary care, secondary care, community services, urgent and emergency care, social care, and informal care. It also collects information needed to estimate costs for economic evaluation. Unit of Measure: Resource use counts and costs (GBP). Resource use will be assessed at baseline (covering the preceding 6 months), month 6, month 12, and month 18 (end of study), and changes over time will be evaluated.

    Time frame: Baseline to 18 months

Other outcomes

  1. Change in plasma pTau-217 concentration

    Exploratory biomarker outcome assessing change in plasma pTau-217 levels (Unit of Measure: pg/mL)

    Time frame: Baseline to 18 months

  2. MRI structural brain changes

    Exploratory Outcome Measures

    Time frame: Baseline to 18 months

  3. Change in plasma amyloid-β concentrations

    Exploratory biomarker outcome assessing change in plasma amyloid-β isoforms (Unit of Measure: pg/mL)

    Time frame: Baseline to 18 months

  4. Change in plasma neurofilament light chain (NfL) concentration

    Exploratory biomarker outcome assessing change in plasma NfL levels (Unit of Measure: pg/mL)

    Time frame: Baseline to 18 months

07

Study locations

2 of 2 sites recruiting
  • Windsor Research Unit
    Cambridge, CB21 5EF, United Kingdom
    Recruiting
  • Two Bridges Research & Development Clinic
    Chertsey, KT16 9AU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Research teams may approach the UCL InCTU (mrcctu.adsmart@ucl.ac.uk) with a formal data-sharing request detailing the specific requirement, proposed research, qualification of researchers and publication plan if they are interested in using AD-SMART data. The request will be reviewed by the trial committees. Data and/or samples will be available for sharing following the end of a trial arm and the unblinding of participants. Researchers wishing to access the AD-SMART Trial data should contact the Trial Management Group in the first instance. Following trial completion, requests for data and/ or sample sharing will be reviewed by an AD-SMART access committee, which will include the trial's Chief Investigators. Data and/ or samples will be shared during the trial according to the CTU's controlled access approach.

Time frame: After publication of primary results

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Mar 2031, 56 months later.

Of 101 phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 73. This study's planned 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Jul 23, 2026
StartEst.
Jul 24, 2026
Primary completionEst.
Mar 2031
CompletionEst.
Mar 2031
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07724132
Collaborators
National Institute for Health Research, United Kingdom, Imperial College London, UK Dementia Research Institute Ltd, Alzheimers Research UK
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Jul 24, 2026 (estimated)
Primary completion
Mar 2031 (estimated)
Completion
Mar 2031 (estimated)
Last update
Jul 23, 2026

Study contacts

Trial Management Team UCL InCTU
Contact
mrcctu.adsmart@ucl.ac.uk
+44 (0)20 7670 4700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion